Not found

Seyed Moghimi, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Biography

Dr. Moghimi earned his Bachelor degree in Biochemistry with Honors from the University of Manchester (UK), and his Doctorate in Biochemistry/Immunobiology from Charing Cross and Westminster Medical School, Imperial College, London. Following postdoctoral training and a University Fellowship at the School of Pharmaceutical Sciences at Nottingham University (UK), he moved to the University of Brighton as a senior lecturer in Biopharmacy and Molecular Therapy. In 2008, he accepted the chair of Nanomedicine at the University of Copenhagen (Denmark), where he currently heads the Nanomedicine Research Group at the School of Pharmacy, Faculty of Health and Medical Sciences. In 2009, he founded the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at the NanoScience Centre of Copenhagen University through a multi-million dollar award by the Strategic Research Council of Denmark, where he acts in the capacity of centre director. Dr. Moghimi is also the honorary professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China) and an elected fellow of the Institute of Nanotechnology in the UK. Since 2009, Dr. Moghimi has secured over US$13 million in competitive research funds in basic and applied nanomedicine research as the principal investigator and is currently a partner in two large-scale competitive European Commission FP-7 programs in translational nanomedicine/drug delivery, addressing Alzheimer’s disease and atherosclerosis with secured budgets of US$ 14.5 million and US$ 11 million, respectively.

Dr. Moghimi serves as the associate editor of Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier) and the Journal of Biomedical Nanotechnology, and sits on the editorial/advisory board of over 15 peer-reviewed international journals, including Advanced Drug Delivery Reviews, Nanomedicine-UK (Future Medicine), and Molecular and Cellular Therapies (BioMed Central). Dr. Moghimi has been a practicing consultant to numerous pharmaceutical, biotechnology, health and food industry companies as well as investment banks, management consultancy firms, and other entrepreneurial enterprises globally for over two decades. He is also a regularly invited assessor and expert evaluator in nanomedicine and pharmaceutical science research centers/research projects for governmental bodies, research councils, and private organizations worldwide (> 50 establishments in 20 countries). As a frequent keynote and guest speaker at many international conferences and organizations, as well as being regular conference chair and organizer, Dr. Moghimi has given over 300 invited speeches and lectures. He has published over 170 peer-reviewed articles in prestigious international journals and book chapters, and is the inventor of many patents.

Description of Research

Dr. Moghimi’s research activities are focused on pharmaceutical nanoscience, nanotechnology in iMedicine, nanotoxicology and fundamental/translational nanomedicine in relation to cancer, neurodegenerative diseases, cardiovascular diseases, and immunological disorders. He has pioneered research in the design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (e.g., splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles, cancer nanomedicine, cerebral endothelial-specific nanoparticle-fiber networks) as well as the molecular basis of nanomaterial immune toxicity, polymer cytotoxicity, and preventive measures.

Areas Of Expertise

Brain targeting Cancer Complement system Nanomedicine Nanotoxicology
Education & Training

PhD , Charing Cross and Westminster Medical School, Imperial College, University of Long, London
Postdoctoral Fellowship , University Hospital of Nottingham
Publications

Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes
Wibroe, PP, Anselmo, AC, Nilsson, PH, Sarode, A, Gupta, V, Urbanics, R, Szebeni, J, Hunter, AC, Mitragotri, S, Mollnes, TE & Moghimi, SM 2017, Nature Nanotechnology. DOI:

In vitro and in vivo differences in murine third complement component (C3) opsonization and macrophage/leukocyte responses to antibody-functionalized iron oxide nanoworms
Wang, G, Griffin, JI, Inturi, S, Brenneman, B, Banda, NK, Michael Holers, V, Moghimi, SM & Simberg, D 2017, Frontiers in Immunology, vol 8, no. FEB, 151. DOI:

Poly-(amidoamine) dendrimers with a precisely core positioned sulforhodamine B molecule for comparative biological tracing and profiling
Wu, LP, Ficker, M, Mejlsøe, SL, Hall, A, Paolucci, V, Christensen, JB, Trohopoulos, PN & Moghimi, SM 2017, Journal of Controlled Release, vol 246, pp. 88-97. DOI:

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions
Anchordoquy, TJ, Barenholz, Y, Boraschi, D, Chorny, M, Decuzzi, P, Dobrovolskaia, MA, Farhangrazi, ZS, Farrell, D, Gabizon, A, Ghandehari, H, Godin, B, La-Beck, NM, Ljubimova, J, Moghimi, SM, Pagliaro, L, Park, JH, Peer, D, Ruoslahti, E, Serkova, NJ & Simberg, D 2017, ACS Nano, vol 11, no. 1, pp. 12-18. DOI:

Complement activation turnover on surfaces of nanoparticles
Moghimi, SM & Simberg, D 2017, Nano Today. DOI:

Smart polymers in drug delivery: A biological perspective
Hunter, AC & Moghimi, SM 2017, Polymer Chemistry, vol 8, no. 1, pp. 41-51. DOI:

ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals
Ordóñez-Gutiérrez, L, Posado-Fernández, A, Ahmadvand, D, Lettiero, B, Wu, L, Antón, M, Flores, O, Moghimi, SM & Wandosell, F 2017, Biomaterials, vol 112, pp. 141-152. DOI:

Nanoparticle Technology: Having Impact, but Needing Further Optimization
Moghimi, SM & Wagner, E 2017, Molecular Therapy. DOI:

AFM visualization of sub-50 nm polyplex disposition to the nuclear pore complex without compromising the integrity of the nuclear envelope
Andersen, H, Parhamifar, L, Hunter, AC, Shahin, V & Moghimi, SM 2016, Journal of Controlled Release, vol 244, pp. 24-29. DOI:

Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo
Chen, F, Wang, G, Griffin, JI, Brenneman, B, Banda, NK, Holers, VM, Backos, DS, Wu, LP, Moghimi, SM & Simberg, D 2016, Nature Nanotechnology. DOI:

Recognition of extremophilic archaeal viruses by eukaryotic cells: A promising nanoplatform from the third domain of life
Uldahl, KB, Wu, L, Hall, A, Papathanasiou, P, Peng, X & Moghimi, SM 2016, Scientific Reports, vol 6, 37966. DOI:

Activation of human complement system by dextran-coated iron oxide nanoparticles is not affected by dextran/Fe ratio, hydroxyl modifications, and crosslinking
Wang, G, Chen, F, Banda, NK, Holers, VM, Wu, LP, Moghimi, SM & Simberg, D 2016, Frontiers in Immunology, vol 7, no. OCT, 418. DOI:

A structurally diverse library of safe-by-design citrem-phospholipid lamellar and non-lamellar liquid crystalline nano-assemblies
Azmi, IDM, Wibroe, PP, Wu, LP, Kazem, AI, Amenitsch, H, Moghimi, SM & Yaghmur, A 2016, Journal of Controlled Release, vol 239, pp. 1-9. DOI:

Call for papers: Nanoparticle Development and Applications in Cellular and Molecular Therapies
Frederickson, RM, Moghimi, SM, Wagner, E & Yla-Herttuala, S 2016, Molecular Therapy, vol 24, no. 8, pp. 1334-1335. DOI:

Nanomedicine: Shadow and substance
Farhangrazi, ZS & Moghimi, SM 2016, . in Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety, and Risk. vol. 2, Pan Stanford Publishing Pte. Ltd. pp. 1081-1090. DOI:

Complement propriety and conspiracy in nanomedicine: Perspective and a hypothesis
Moghimi, SM 2016, Nucleic Acid Therapeutics, vol 26, no. 2, pp. 67-72. DOI:

Soluble and immobilized graphene oxide activates complement system differently dependent on surface oxidation state
Wibroe, PP, Petersen, SV, Bovet, N, Laursen, BW & Moghimi, SM 2016, Biomaterials, vol 78, pp. 20-26. DOI:

An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome
Wibroe, PP, Ahmadvand, D, Oghabian, MA, Yaghmur, A & Moghimi, SM 2016, Journal of Controlled Release, vol 221, pp. 1-8. DOI:

Nanoparticle patterning for biomedicine
Moghimi, SM 2016, BioImpacts, vol 6, no. 4, pp. 183-185.

Platelet mimicry: The emperor's new clothes?
Moghimi, SM, Hunter, AC & Peer, D 2016, Nanomedicine: Nanotechnology, Biology, and Medicine, vol 12, no. 1, pp. 245-248. DOI: